Evidence map›Paper›PMID 39101192›Full record

ArticleDiabetology international2024

A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab.

Kota Nishihama, Yuko Okano, Chisa Inoue, Kanako Maki, Kazuhito Eguchi, Soichiro Tanaka, Atsuro Takeshita, Mei Uemura, Taro Yasuma, Toshinari Suzuki and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kota NishihamaDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.
Yuko OkanoDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.
Chisa InoueDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.
Kanako MakiDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.
Kazuhito EguchiDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.
Soichiro TanakaDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.
Atsuro TakeshitaDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.
Mei UemuraDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.
Taro YasumaDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.
Toshinari SuzukiDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.
Esteban C GabazzaDepartment of Immunology, Mie University Graduate School of Medicine, Tsu, Japan.
Yutaka YanoDepartment of Diabetes, Metabolism, and Endocrinology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie 514-8507 Japan.ORCID 0000-0003-0234-1207

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The case was an 80-year-old Japanese man. He was diagnosed with right renal cell carcinoma when he was 74. After laparoscopic radical nephrectomy, the patient received interferon, sorafenib, axitinib, and nivolumab therapy. The patient developed rapid progressive insulin-dependent diabetes mellitus (DM) after 46 courses of nivolumab monotherapy (772 days from the first nivolumab treatment). Glutamic acid decarboxylase antibody, islet cell cytoplasmic antibody, islet cell antigen-2 antibody, insulin antibody, and zinc transporter 8 antibody were all negative. Human leukocyte antigen (HLA) typing showed DRB1*09:01, DRB1 *13:02, DQB1*03:03, and DQB1 *06:04. Multiple daily insulin injections were started. However, controlling his blood glucose by standard multiple daily insulin injection treatments was difficult. The patient survived more than two years after the onset of immune checkpoint inhibitor-associated DM (ICI-DM). This is a valuable report of late-onset ICI-DM with a detailed patient background and clinical course over two years after the first dose of nivolumab.

Indexed as

Immune checkpoint inhibitorImmune-related adverse eventsNivolumabType 1 diabetes mellitus

Identifiers

PMID39101192
PMCPMC11291771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.